A monthly dose of the drug Zalbin has proved equally effective as the weekly dose of the drug. This has been revealed by a mid-stage study.

Scientiist Mani Subramanium is of the opinion that a one third reduction in the dosage of the drug proves to be very effective in the treatment of genome 2 and 3 type hepatitis C.

This study has been an endeavor of the Human Genome Sciences Inc. and Novartis. This news can be taken as a welcome change from the practice of obtaining weekly doses of the drug.

Consumers can now feel glad and relieved at the revelation. For one, they no longer have to go through the hassle of ensuring a weekly intake of the drug. On the other hand, the cost of a single dose of the drug will be cheaper than the cost of receiving the drug weekly.

Patients will be benefited from all angles. A single dose requirement will not only make it easier for authorities to administer the drug, it will also make it facile for them to maintain a record of the patients who have received it. The load of maintaining a record of weekly administration of the drug is definitely higher than the load of maintaining a record of administration of monthly doses of the drug.

Moreover, it is also convenient for patients to receive the drug only once in a month. The news is of special importance to people who live in areas where medical aid and facilities are not easily accessible. Some even have to travel a few miles to receive doses of the drug.

The finding that a monthly dose of the drug will suffice, will not only make the administration of the drug easy but also encourage people from far flung areas to come to places where the drug is available.

It is a matter of plain and simple mathematics. An economical single trip versus 4 cumbersome trips in a month! One can easily do the math.